The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
 
Keitaro Shimozaki
No Relationships to Disclose
 
Izuma Nakayama
No Relationships to Disclose
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Senju Pharmaceutical; Toray Industries
 
Koichiro Yoshino
No Relationships to Disclose
 
Koshiro Fukuda
No Relationships to Disclose
 
Shota Fukuoka
No Relationships to Disclose
 
Hiroki Osumi
No Relationships to Disclose
 
Mariko Ogura
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Akira Ooki
Honoraria - Bristol Myers Squibb Foundation; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Keisho Chin
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)